Chukwuemeka C, Ndubueze C, Kolawole A, Joseph J, Oladipo I, Ofoezie E
Blood Sci. 2024; 7(1):e00215.
PMID: 39726795
PMC: 11671056.
DOI: 10.1097/BS9.0000000000000215.
Zhuo Q, Zhang Z, Fang X
EJHaem. 2024; 5(6):1301-1311.
PMID: 39691252
PMC: 11647694.
DOI: 10.1002/jha2.1051.
Ju H, Sohn Y, Nam Y, Rim Y
Stem Cell Res Ther. 2024; 15(1):142.
PMID: 38750578
PMC: 11094930.
DOI: 10.1186/s13287-024-03754-9.
Jiang J, Ren R, Cheng Y, Li X, Zhang G
Front Cell Dev Biol. 2024; 11:1327466.
PMID: 38250324
PMC: 10796611.
DOI: 10.3389/fcell.2023.1327466.
Cho Y, Kim H, Kwon S, Jeon S, Cheong J, Nam K
Stem Cell Res Ther. 2023; 14(1):106.
PMID: 37101221
PMC: 10132444.
DOI: 10.1186/s13287-023-03305-8.
An allied reprogramming, selection, expansion and differentiation platform for creating hiPSC on microcarriers.
Lam A, Ho V, Vassilev S, Reuveny S, Oh S
Cell Prolif. 2022; 55(8):e13256.
PMID: 36574589
PMC: 9357361.
DOI: 10.1111/cpr.13256.
Selection of O-negative induced pluripotent stem cell clones for high-density red blood cell production in a scalable perfusion bioreactor system.
Yu S, Vassilev S, Lim Z, Sivalingam J, Lam A, Ho V
Cell Prolif. 2022; 55(8):e13218.
PMID: 35289971
PMC: 9357363.
DOI: 10.1111/cpr.13218.
Industrially Compatible Transfusable iPSC-Derived RBCs: Progress, Challenges and Prospective Solutions.
Lim Z, Vassilev S, Leong Y, Hang J, Renia L, Malleret B
Int J Mol Sci. 2021; 22(18).
PMID: 34575977
PMC: 8472628.
DOI: 10.3390/ijms22189808.
A Scalable Suspension Platform for Generating High-Density Cultures of Universal Red Blood Cells from Human Induced Pluripotent Stem Cells.
Sivalingam J, SuE Y, Lim Z, Lam A, Lee A, Lim H
Stem Cell Reports. 2020; 16(1):182-197.
PMID: 33306988
PMC: 7897557.
DOI: 10.1016/j.stemcr.2020.11.008.
Human induced pluripotent stem cell line banking for the production of rare blood type erythrocytes.
Park Y, Jeon S, Kim H, Suh E, Choi S, Kim S
J Transl Med. 2020; 18(1):236.
PMID: 32532292
PMC: 7291485.
DOI: 10.1186/s12967-020-02403-y.